Jump to Navigation

Facebook Connect

User login

2017 Spring CLU Registration Now Open

Registration is now open for the 2017 Spring Clinical Lipid Update February 24-26 at the Hyatt Regency Phoenix! Visit lipid.org/springclu for more information, or to register!

Call for Abstracts for the 2017 NLA Scientific Sessions

Abstracts for the 2017 National Lipid Association Scientific Sessions in Philadelphia May 18-21, 2017, are now open. Submitted abstracts will be considered for the poster hall and oral presentations during the abstract session at the meeting. All accepted abstracts will be published in the... read more

ICD-10 Codes for Familial Hypercholesterolemia Now in Effect

The new ICD-10 Codes released by the Center for Medicare & Medicaid Services (CMS) are now in effect. The codes became effective October 1, 2016.  The two new specific codes for FH are:

  • E78.01: Familial hypercholesterolemia
  • Z83.42: Family history of familial... read more

Check Out the Latest Issue of LipidSpin

The National Lipid Association recently released its latest issue of LipidSpin – the 2016 Potpourri freelance edition. To download the issue and/or view the articles, visit lipid.org/lipidspin/all

NLA – Chief Science Officer Nominations Open

The National Lipid Association (NLA) is seeking nominations for the Chief Science Officer (CSO) position for the 2017-2020 term, beginning at the 2017 NLA annual Scientific Sessions and ending at the conclusion of the 2020 annual Scientific Sessions.  The nomination requirements... read more

Foundation to Launch Rare Disease Campaign in Conjunction with National Cholesterol Education Month

The Foundation of the National Lipid Association, in conjunction with National Cholesterol Education Month, will launch the RADAR Campaign (RADAR: RAre Disease AwaReness) providing resources and tools to both patients and healthcare professionals designed to help improve the identification and... read more

Challenges in Prescribing PCSK9 Inhibitors Survey

The National Lipid Association (NLA) is committed to enhancing the practice of lipid management in clinical medicine. A major component is having access to all therapies to properly treat patients with the management of lipid disorders. PCSK9 inhibitors are one therapy that patients have... read more

by Dr. Radut.